AARTIDRUGSNSEAARTI DRUGS LTD.· PharmaceuticalsCriticalNegative
Announced Fri, 31 Jul · 20:10 IST

Aarti Drugs: CEO Prakash Patil retires; Adhish Patil named MD, Gogri becomes Chairman

Ceo ResignedCfo ResignedPromoter Family Board EntryKmp ResignedManagement Changes View source PDFExplain this filing

AARTIDRUGS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹423.00
prior close
₹424.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.7-3.0-2.7-3.0-2.4-2.7-2.8-1.1+0.0+2.4-0.1+0.5
Up moveDown movePending
AI summary

Aarti Drugs' Chairman, MD and CEO Prakash M. Patil will retire from September 30, 2026, ahead of his scheduled May 2027 term end, citing an orderly leadership transition. Existing MD Rashesh C. Gogri (promoter group) will add Chairman role from October 1, 2026. CFO Adhish P. Patil, son of the outgoing Chairman, will be elevated to MD for 5 years. Uday M. Patil retires after 25 plus years. Board committees are reconstituted.

Likely market impact

Pre-planned transition with promoter family succession; Adhish Patil as new MD, Gogri as Chairman. Subject to shareholder approval at next AGM.